Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesRadiology/Diagnostic Imagingevicore Pelvis Imaging Coverage Update | OpenPayer
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentevicorePolicy N/A

    Pelvis Imaging Guidelines

    Customize your policy alerts

    Sign up for all evicore policy alerts

    Know when evicore releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage and utilization guidance for pelvic imaging modalities (ultrasound, MRI, CT, and related procedures) for plans administered by Cigna and reviewed by eviCore; affects ordering providers, radiology reviewers, and medical directors determining medical necessity.

    Policy Summary
    Payerevicore
    PolicyPelvis Imaging Guidelines
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateSep 1, 2026
    Next Review DateN/A
    Key ActionObtain and document a pregnancy test and perform pelvic/transvaginal ultrasound as the initial imaging step before ordering advanced CT or MRI when clinically appropriate.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2026-09-01effective date
    v2.0.2026document version
    3pelvic MRI CPT codes listed
    23D rendering CPT codes cited
    Ultrasound first-linepreferred initial imaging

    Coverage Criteria and Indications

    General coverage criteria for pelvic imaging

    Covered when ALL of the following are met as described in general guidelines and modality-specific sections:

    Clinical evaluation: A current clinical evaluation since onset or change in symptoms is required before advanced imaging; includes relevant history, physical exam (including pelvic/urologic exam), appropriate laboratory studies, and non-advanced imaging such as plain x-ray or pelvic/transvaginal/transperineal ultrasound

    Other meaningful contact (telehealth, telephone, electronic messaging) may substitute for face-to-face evaluation

    Pregnancy and modality preference: When medically necessary, pregnant individuals should be evaluated with ultrasound or MRI without contrast; CT is reserved for select situations with radiation protection

    Use obstetrical CPT codes when pregnancy test is positive; gynecology CPT codes (e.g., 76830/76856/76857) are not supported for pregnant individuals

    Ultrasound-first approach: Transvaginal ultrasound (CPT 76830) is the standard first-line modality for adult female pelvic organ pathology; pelvic ultrasound (CPT 76856/76857) may complement or substitute in pediatric or non-sexually active individuals; transperineal ultrasound (CPT 76872) is appropriate for suspected urethral or perineal/vaginal pathology
    Policy Summary
    Payerevicore
    PolicyPelvis Imaging Guidelines
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateSep 1, 2026
    Next Review DateN/A
    Key ActionObtain and document a pregnancy test and perform pelvic/transvaginal ultrasound as the initial imaging step before ordering advanced CT or MRI when clinically appropriate.
    SourceLink
    On This Page
    Coverage Criteria and IndicationsCovered Indications (Modality-Specific)CPT and Procedural CodesProvider Responsibilities, Prior Authorization, and DocumentationPrior Authorization and High-Tech ImagingContrast and Pregnancy ConsiderationsImaging Frequency and Follow-up IntervalsNot Medically Necessary / Not CoveredDefinitions and Key TermsBackground and Scope

    CT is limited and not medically necessary for routine evaluation of pelvic soft-tissue anatomy due to poor soft-tissue contrast resolution

    3D/4D rendering and Doppler adjuncts: 3D/4D ultrasound rendering (CPT 76376/76377) and Duplex/Color Doppler (CPT 93975/93976) are medically necessary only as specified in condition-specific sections (e.g., equivocal intra-cavitary lesions, suspected uterine anomaly, lost IUD, indeterminate infertility ultrasound, surgical planning) and are not routine for simple cyst evaluation

    See condition-specific sections for indications

    Imaging documentation and coding: Ordering documentation must support initial use of ultrasound and rationale for advanced imaging when requested; when 3D rendering or pelvic MRI are billed, report appropriate CPTs (76376/76377; 72195/72196/72197) per guidance

    Pregnancy test result must be documented for premenopausal individuals when relevant

    Medically necessary uses of 3D/4D ultrasound rendering

    3D/4D ultrasound rendering (CPT 76376 or 76377) is medically necessary in the following clinical scenarios:

    Intra-cavitary lesion: Uterine intra-cavitary lesion when initial ultrasound is equivocal

    See Abnormal Uterine Bleeding and Leiomyoma sections

    Hydrosalpinx/peritoneal cyst: Hydrosalpinges or peritoneal cysts when initial ultrasound is equivocal

    See Complex Adnexal Masses section

    Lost IUD (inability to feel or see IUD string) when initial ultrasound is non-diagnostic

    See IUD localization section

    Suspected uterine anomaly on ultrasound

    See Congenital Uterine Anomalies section

    Infertility indeterminate ultrasound: Infertility when ultrasound is indeterminate or there is clinical suspicion for intracavitary lesion, hydrosalpinx, uterine synechia, adenomyosis, or uterine anomalies

    See Initial Infertility Evaluation section

    Obstetrical implantation concerns: Abnormal pregnancy implantation (e.g., suspected C-section scar pregnancy or cornual/interstitial ectopic) or to locate an IUD in pregnancy-related scenarios

    3D-4D rendering medically necessary in select obstetrical scenarios

    Fetal surgical planning: Surgical planning for complex fetal malformations (e.g., complex congenital heart disease) where 3D/4D aids operative planning

    See fetal imaging guidance

    Modality selection and medical necessity

    Modality selection guidance and medical necessity stance:

    Ultrasound-first; MRI second-line: Ultrasound (transvaginal CPT 76830; transabdominal/pelvic CPT 76856/76857) is the recommended first-line modality for pelvic organ evaluation; MRI pelvis (CPT 72195/72197) is medically necessary as a targeted, second-line study when ultrasound is inconclusive or when superior soft-tissue characterization or surgical planning is required

    Transperineal ultrasound may be used when transvaginal approach is not appropriate

    CT stance: CT is not medically necessary for routine evaluation of pelvic soft-tissue anatomy due to limited soft-tissue contrast resolution; CT may be considered only in select situations (including some pregnancy circumstances) when benefits outweigh risks

    Avoid CT as primary pelvic soft-tissue modality

    Abnormal Uterine Bleeding (AUB) - Initial evaluation

    Covered when ALL of the following are met

    Pregnancy test should be performed initially in premenopausal individuals before imaging for abnormal uterine bleeding

    Positive pregnancy requires obstetrical imaging pathway

    Initial evaluation (pregnancy negative or postmenopausal): Initial evaluation includes pelvic ultrasound (CPT 76856 or 76857) and/or transvaginal ultrasound (CPT 76830) and consideration of D&C and/or endometrial biopsy as clinically indicated

    Endometrial sampling is gold standard when concern for malignancy or abnormal strip

    Adjuncts when ultrasound equivocal: When ultrasound is equivocal for intracavitary lesions, Duplex/Color Doppler (CPT 93975/93976) and/or 3-D rendering (CPT 76377) may be added as adjuncts

    See condition-specific sections

    Endometrial concern: Individuals with thickened or indistinct endometrial strip or continued bleeding should undergo endometrial biopsy to rule out carcinomaendometrial strip >4 mm may prompt sampling

    Imaging alone does not replace tissue sampling

    Retained Products of Conception (RPOC)

    Covered when ALL of the following are met

    Initial ultrasound: Pelvic ultrasound (CPT 76856/76857) and/or transvaginal ultrasound (CPT 76830) is medically necessary one time for suspected retained products of conception; repeat ultrasound is medically necessary for continued symptoms

    Color Doppler may be added to aid diagnosis

    Adjuncts: Color Doppler ultrasonography (CPT 93975 or CPT 93976) may be added to ultrasound to aid in diagnosis of RPOC
    When ultrasound equivocal for surgical planning: If ultrasound with color Doppler is equivocal and further imaging is needed for surgical planning, CT pelvis with and without contrast (CPT 72194) OR MRI pelvis with and without contrast (CPT 72197) is medically necessary

    Prefer MRI for soft tissue characterization when appropriate

    Amenorrhea (Primary and Secondary) - Imaging and workup

    Covered when ALL of the following are met

    Pregnancy test should be done initially in evaluation of amenorrhea

    If pregnancy positive, follow obstetrical imaging policies and codes

    Laboratory and ultrasound evaluation (pregnancy negative): When pregnancy test is negative, obtain laboratory evaluation as clinically indicated (e.g., FSH, TSH, estradiol, prolactin; testosterone/DHEAS if hyperandrogenism suspected) and perform pelvic ultrasound (CPT 76856/76857) and/or transvaginal ultrasound (CPT 76830) to assess uterine or ovarian pathology

    Results guide further testing and specialty referral

    Asherman's workup: If hysterosalpingogram (CPT 74740), sonohysterosalpingography (CPT 76831), or hysteroscopy is indeterminate for Asherman's syndrome, MRI pelvis without contrast (CPT 72195) or MRI pelvis without and with contrast (CPT 72197) is medically necessary

    Primary Amenorrhea

    Initial pelvic ultrasound (transabdominal and/or transvaginal) is medically necessary if ANY of the following are present:

    Primary Amenorrhea - Indications: Normal pubertal development with negative pregnancy test; indeterminate or unable pelvic exam; delayed puberty with elevated FSH or LH for age/Tanner stage; suspected pituitary/hypothalamic tumor (refer to head imaging); ultrasound identifies absence of uterus (consider karyotype/testosterone)

    Transvaginal ultrasound is medically necessary in pediatric individuals who are sexually active or use a tampon and consent to the study.

    Adenomyosis

    Transvaginal ultrasound and/or pelvic ultrasound is the medically necessary first-line study; MRI pelvis is medically necessary as second-line when:

    MRI indications for adenomyosis: MRI pelvis (CPT 72195 or CPT 72197) is medically necessary when ultrasound is inconclusive and further delineation would affect management, to guide treatment in enlarged uterus with coexisting leiomyoma after indeterminate ultrasound, or when uterine artery embolization is being considered

    Duplex Doppler (CPT 93975/93976) can be added if requested

    Adnexal Mass - Initial Evaluation

    When a potential adnexal mass is identified, the following imaging pathway is indicated:

    Initial study: Transvaginal ultrasound (CPT 76830) is the medically necessary initial study; pelvic ultrasound (CPT 76856/76857) may be complementary. Color Doppler may be necessary to evaluate vascularity. If ultrasound cannot identify origin, MRI pelvis (CPT 72195/72197) is medically necessary. For O-RADS 0, repeat ultrasound OR MRI pelvis is medically necessary. If pregnant, MRI pelvis without contrast (CPT 72195) is preferred to avoid gadolinium exposure.

    Simple cysts ≤10 cm are almost universally benign

    Simple cyst follow-up (≤10 cm)

    Covered when follow-up imaging meets the size- and menopausal-status based schedule below

    Simple cysts ≤3 cm: Pre-menopausal: no follow-up required. Post-menopausal: no follow-up required.≤3 cm
    Simple cyst >3 cm to 5 cm: Pre-menopausal: no follow-up required. Post-menopausal: follow-up in 12 months with TV and/or pelvic ultrasound; if smaller (≥10–15% decrease) stop surveillance; if stable repeat at 24 months; if enlarging (≥10–15% increase) follow at 12 and 24 months.>3–5 cm
    Simple cyst >5 cm to ≤10 cm: Pre-menopausal: follow-up in 8–12 weeks (proliferative phase if possible) with TV and/or pelvic ultrasound. Post-menopausal: follow-up in 3–6 months with TV and/or pelvic ultrasound. Subsequent annual follow-up until stable for 2 years or decreasing, then no further imaging.>5–≤10 cm

    Simple cysts >10 cm

    Covered imaging and indications for larger simple cysts

    Size >10 cm: If not excised, ultrasound follow-up within 6 months with TV and/or pelvic ultrasound is medically necessary; if stable, follow at 12 and 24 months. If solid component or ultrasound equivocal or changing morphology/vascularity, MRI pelvis without and with contrast (CPT 72197) is medically necessary.>10 cm

    Complex adnexal masses (O-RADS based and specific lesion types)

    Covered when criteria below are met based on lesion type, O-RADS, menopausal status, and imaging findings

    Complex cyst features: Ultrasound should characterize cyst/mass prior to advanced imaging; complex features include solid areas, debris, irregular septations >3 mm, mural nodules with Doppler flow, or free fluid (often O-RADS ≥2)

    Routine 3D rendering not necessary for most complex cysts

    Hemorrhagic cyst (<10 cm): Pre-menopausal: if ≤5 cm no further imaging; if >5 to <10 cm follow-up in 8–12 weeks with pelvic and/or TV ultrasound; duplex (CPT 93975/93976) may be added. If enlarging or not resolved, MRI (CPT 72197) is medically necessary. Post-menopausal: follow 2–3 months or MRI CPT 72197 as indicated.<10 cm
    Hemorrhagic cyst ≥10 cm: Pre-menopausal: consider MRI CPT 72197 if ultrasound equivocal; follow-up ultrasound within 6 months if not excised; MRI if solid component or changing morphology. Post-menopausal: MRI CPT 72197 supported.>=10 cm
    Endometrioma: Typical endometriomas <10 cm: if equivocal on ultrasound consider MRI CPT 72197; if confirmed and not excised follow-up ultrasound in 12 months (stable at 24 months then stop). ≥10 cm follow similar to other ≥10 cm lesions. Post-menopausal: consider MRI or short-interval ultrasound.
    Dermoid: Typical dermoid <10 cm: if equivocal consider MRI or short-interval ultrasound; if ≥10 cm follow-up within 6 months and consider MRI for solid components or changing morphology. Post-menopausal similar to pre-menopausal.
    One-time MRI indications: One-time MRI pelvis without and with contrast (CPT 72197) is medically necessary to follow masses not well visualized by ultrasound, unexplained change on follow-up, patient risk factors (family history or abnormal biomarkers), to differentiate origin when unclear, O-RADS 3 with solid component, O-RADS 4 or 5, or concern for metastatic ovarian malignancy

    Imaging coverage criteria for suspected endometriosis

    Covered when the following modality-specific criteria are met:

    Ultrasound first-line for endometriosis: Transvaginal ultrasound (CPT 76830) and/or transabdominal pelvic ultrasound (CPT 76856/76857) is medically necessary as the first-line diagnostic exam for suspected endometriosis
    MRI pelvis indications: MRI pelvis (CPT 72195 or CPT 72197) is medically necessary prior to planned surgery for suspected deep pelvic endometriosis (e.g., rectovaginal, deeply infiltrative bladder disease, cul-de-sac obliteration); to characterize complex adnexal masses as endometrioma if ultrasound is equivocal; for suspected abdominal wall or cesarean scar endometriosis when ultrasound is inconclusive

    Refer to chest imaging guideline for thoracic endometriosis

    PID Imaging - Initial and Advanced

    Imaging is covered when criteria below are met:

    Initial imaging with ultrasound for PID/TOA: Pelvic ultrasound (transabdominal and/or transvaginal CPT 76856/76857/76830) is medically necessary as the initial study when diagnosis is uncertain after bimanual pelvic exam and laboratory testing; color Doppler may be added
    Advanced imaging indications for PID/TOA: CT pelvis with contrast (CPT 72193) OR MRI pelvis with and without contrast (CPT 72197) is medically necessary if diagnosis remains uncertain after exam, labs, and ultrasound; if ultrasound shows extensive abscess formation and further imaging is needed for treatment planning; or for suspected TOA with inconclusive ultrasound

    PCOS Imaging and Pre-Imaging Laboratory Requirements

    Ultrasound is covered when clinical/lab suspicion exists; specific labs recommended before advanced imaging:

    When ultrasound is medically necessary for PCOS: Pelvic ultrasound (CPT 76856/76857 and/or 76830) is medically necessary when history, exam, and/or laboratory findings are suspicious for PCOS
    Laboratory testing prior to advanced imaging: Obtain virilizing hormone levels (Testosterone and DHEAS) and exclude mimicking disorders by measuring TSH, Prolactin, and 17-OHP; consider additional testing (Cortisol, ACTH, dexamethasone suppression, IGF-1, FSH, LH, estradiol) based on presentation before proceeding to advanced imaging

    Initial Infertility Evaluation

    Initial infertility evaluation — covered when the following are met

    Initial infertility ultrasound: A one-time pelvic ultrasound (CPT 76856 or 76857) and/or transvaginal ultrasound (CPT 76830) is medically necessary for initial infertility workup

    Repeat or serial ultrasounds for initial infertility workup are not medically necessary

    Tubal Patency

    To evaluate for tubal patency

    Tubal patency testing: Hysterosalpingography (CPT 74740) OR Sonohysterosalpingography (CPT 76831) is medically necessary to evaluate tubal patency

    Adjunct Ultrasound Imaging

    When ultrasound is indeterminate or there is clinical suspicion for intracavitary or structural uterine pathology

    Adjunct ultrasound options: 3D ultrasound imaging (add-on CPT 76377) OR ultrasound Color Doppler (CPT 93975 or CPT 93976) are medically necessary adjuncts when ultrasound is indeterminate

    IUD localization

    Imaging for 'lost' IUD or malpositioned IUD

    Initial evaluation: Transabdominal and/or transvaginal ultrasound is the first-line imaging for suspected malpositioned or lost IUD

    Ultrasound preferred due to availability and no ionizing radiation

    If ultrasound and plain x-ray negative or non-diagnostic: CT pelvis without contrast (CPT 72192) OR CT abdomen and pelvis without contrast (CPT 74176) OR MRI pelvis without contrast (CPT 72195) are medically necessary to locate a 'lost' IUD

    If ultrasound non-diagnostic and pregnancy test negative, obtain X-ray before CT/MRI; CT/MRI useful for extrauterine migration/perforation

    Pregnancy positive: If pregnancy test is positive, gynecology ultrasound CPT codes are not supported; use obstetrical CPT codes and follow obstetrical imaging guidance

    Implantable Contraceptive Devices

    Implantable contraceptive device imaging

    Radiopaque implant not palpable: If implant cannot be palpated and is radiopaque, initial imaging should include ultrasound or X-ray of the arm; if thoracic migration suspected, consider chest x-ray then CT chest (CPT 71250/71260) or CTA chest (CPT 71275) if equivocal
    Radiolucent implant not palpable: If implant is radiolucent, initial imaging should include ultrasound of the arm; MRI upper extremity without contrast (CPT 73218) is medically necessary if ultrasound is equivocal
    Thoracic migration: If thoracic implant migration suspected, MRI chest without or without and with contrast (CPT 71550 or CPT 71552) is medically necessary

    Hysteroscopically Placed Tubal Occlusion Device

    Hysteroscopically placed tubal occlusion device — imaging indications

    TV or pelvic ultrasound indicated: Transvaginal ultrasound (CPT 76830) and/or pelvic ultrasound (CPT 76856 or CPT 76857) are medically necessary if there is suspected complication of a hysteroscopically placed tubal occlusion device (abnormal device position, uterine perforation, severe pain, excessive bleeding)

    IUD localization imaging pathway

    Covered when following imaging workflow is followed for suspected malpositioned IUD:

    Step 1: Perform transabdominal and/or transvaginal ultrasound as the initial imaging to locate a malpositioned IUD

    Ultrasound preferred due to no ionizing radiation

    Step 2: If ultrasound is non-diagnostic and pregnancy test is negative, obtain plain X-ray to identify radiopaque IUD or diagnose expulsionpregnancy test negative

    If IUD not visualized on X-ray, expulsion can be diagnosed

    Step 3: If both ultrasound and X-ray are equivocal, CT or MRI may be used to delineate IUD position and relationship to abdominal organs

    CT/MRI useful for extrauterine migration/perforation assessment

    Pelvic pain (female) imaging pathway

    Covered when ALL of the following initial steps are met:

    Initial evaluation: Perform history, physical exam, laboratory testing, and pregnancy test in premenopausal females

    Guides subsequent imaging workup

    Initial imaging: Ultrasound (transvaginal CPT 76830 and/or pelvic CPT 76856/76857) is the initial imaging modality for suspected gynecologic pelvic pain; color/power Doppler may be used to assess vascular flow
    Indications for duplex Doppler: Duplex Doppler (CPT 93975 or CPT 93976) is medically necessary if there is an ovarian mass and/or suspicion of ovarian torsion on initial ultrasound, or for chronic pelvic pain (≥6 months)pelvic pain >= 6 months
    Advanced imaging after equivocal ultrasound: If ultrasound is equivocal for chronic pelvic pain or for surgical planning, CT pelvis with contrast (CPT 72193) OR MRI pelvis (CPT 72195 or CPT 72197) is medically necessary

    Choice depends on clinical question; MRI superior for soft tissue

    Proctalgia evaluation: After appropriate clinical/exam/endoscopy, endoanal ultrasound (CPT 76872), MRI pelvis with and without contrast (CPT 72197), or CT pelvis with contrast (CPT 72193) are medically necessaryprior endoscopy/clinical evaluation performed

    Suspected Uterine Mass (PV-12.0)

    Covered when ALL of the following are met

    Initial evaluation for suspected uterine mass: A potential mass found on exam and/or incidentally on other imaging; transvaginal ultrasound (CPT 76830) is the medically necessary initial study

    Leiomyoma/Uterine Fibroids (PV-12.1)

    Covered when ANY of the following clinical indications are present

    Leiomyoma imaging indications: Pelvic ultrasound (CPT 76856/76857) and/or transvaginal ultrasound (CPT 76830) are medically necessary for suspected leiomyoma with pelvic pain, suspected ureteral obstruction, pelvic pressure, abnormal uterine bleeding, or enlarged uterus on exam (with negative pregnancy test if premenopausal); pre-operative imaging prior to myomectomy; recurrent symptoms; and surgical planning where 3-D rendering or Doppler is indicated

    Includes CPT 76377 and 93975/93976 as specified

    MRI pelvis necessity: MRI pelvis (CPT 72197 or CPT 72195) is medically necessary to guide treatment when ultrasound is indeterminate for planned myomectomy, suspected leiomyoma necrosis, planning radiofrequency ablation, or when uterine artery embolization is being considered; MRA (72198) or CTA (72191) may be used if MRI equivocal or requested for embolization planning
    Suspected leiomyosarcoma: MRI pelvis with and without contrast (CPT 72197) is medically necessary for suspected leiomyosarcoma when suggestive ultrasound features and symptoms are present (features include size >8 cm, irregular borders, cystic change/necrosis, increased vascularity, rapid growth); symptoms include new/rapid enlargement particularly postmenopausal or rapid growth in premenopausal patientssize >8 cm

    Endometrial Polyp (PV-12.2)

    Covered when ALL of the following are met

    Endometrial polyp evaluation: Transvaginal ultrasound (CPT 76830) is the medically necessary initial study; pelvic ultrasound (CPT 76856/76857) is complementary if requested; 3-D rendering (CPT 76377/76376) is medically necessary for intracavitary lesion delineation; hysteroscopy remains the gold standard for diagnosis and treatment

    If biopsy confirms malignancy, follow oncology guideline

    Asymptomatic Thickened Endometrium (PV-12.3)

    Covered when individualized assessment indicates

    Asymptomatic thickened endometrium: Incidental thickened endometrium (>4 mm) in a postmenopausal individual without bleeding does not routinely require evaluation; individualized assessment including endometrial sampling based on risk factors is medically necessary>4 mm

    Advanced imaging not medically necessary for EIN-AEH

    Periurethral cysts / initial evaluation

    Initial evaluation includes any of the following:

    Initial pelvic ultrasound options: Pelvic ultrasound (CPT 76856 or CPT 76857) and/or transvaginal ultrasound (CPT 76830) and/or transperineal ultrasound (CPT 76872) is medically necessary for initial evaluation of periurethral cysts and vaginal masses

    MRI pelvis (CPT 72197) is available for surgical planning when ultrasound equivocal

    MRI Pelvis for surgical planning or equivocal ultrasound

    MRI pelvis for surgical planning: MRI pelvis without and with contrast (CPT 72197) is medically necessary for surgical planning when ultrasound is equivocal or for surgical planning of vaginal masses/urethral diverticula

    Urethral diverticula evaluation

    Urethral diverticula imaging: Pelvic/transvaginal/transperineal ultrasound are appropriate initial evaluations but not required prior to advanced imaging; urethrography or CT urethrography (CPT 72194/72193) is medically necessary to evaluate urethral abnormalities; MRI pelvis (CPT 72197) is medically necessary for surgical planning

    MRI sensitivity is high for urethral diverticula

    Congenital uterine anomalies

    This guideline is intended for congenital uterine anomalies.

    Initial imaging for uterine anomalies: Pelvic ultrasound (CPT 76856 or 76857) and/or transvaginal ultrasound (CPT 76830) is medically necessary for initial evaluation; 3-D rendering (CPT 76377) may be an add-on if uterine anomaly suspected on ultrasound

    Congenital Uterine Anomalies - Medical Necessity

    Covered when specific conditions are met for congenital uterine anomalies

    Initial evaluation: Pelvic ultrasound (CPT 76856/76857) and/or transvaginal ultrasound (CPT 76830) is medically necessary for initial evaluation; 3D rendering (CPT 76377) may be an add-on if uterine anomaly suspected on ultrasound
    If ultrasound indeterminate: sonohysterosalpingography (CPT 76831) is medically necessary; retroperitoneal ultrasound (CPT 76770 or 76775) is medically necessary to evaluate for coexisting renal anomalies if a complex uterine anomaly is present; MRI abdomen or CT urography (CPT 74181/74183 or CPT 74178) is medically necessary for indeterminate renal anomalies
    MRI pelvis for complex anomalies: MRI pelvis without and with contrast (CPT 72197) is medically necessary when ultrasound is indeterminate for a complex uterine anomaly or when requested for surgical planning of a previously diagnosed uterine anomaly

    An arcuate uterus is a normal variant; advanced imaging of a known arcuate uterus is not medically necessary

    Congenital Vaginal Anomalies - Medical Necessity

    Covered when specific conditions are met for congenital vaginal anomalies

    Initial evaluation: Pelvic ultrasound (CPT 76856/76857) and/or transvaginal ultrasound (CPT 76830) and/or transperineal/translabial ultrasound (CPT 76872/76857) are medically necessary for initial evaluation; 3D rendering (CPT 76377/76376) is an add-on if vaginal anomaly suspected on ultrasound
    MRI pelvis for complex vaginal anomalies: MRI pelvis without and with contrast (CPT 72197) is medically necessary when ultrasound is indeterminate for a complex vaginal anomaly or when requested for surgical planning of a previously diagnosed vaginal anomaly

    Fetal and Pregnancy-related Pelvic Imaging

    Pregnancy and fetal-related pelvic imaging

    Fetal MRI use: Fetal MRI (CPT 74712; 74713 for additional fetus) is used when fetal imaging is required; do not report fetal MRI CPTs in conjunction with pelvic MRI CPTs (72195/72196/72197). If only placenta or maternal pelvis is imaged without fetal imaging use MRI pelvis (CPT 72195)

    eviCore does not review fetal MRI for Cigna

    Placenta accreta indications: MRI pelvis without contrast (CPT 72195) is medically necessary if ultrasound is indeterminate or advanced imaging is needed for surgical planning of placenta accreta spectrum
    Ectopic pregnancy imaging: For suspected cornual, interstitial, or C-section scar ectopic pregnancy: 3D rendering (CPT 76377) and/or Color Doppler (CPT 93976) are medically necessary with ultrasound; MRI pelvis without contrast (CPT 72195) is medically necessary if ultrasound is inconclusive

    Abnormal NIPT — Maternal Malignancy Workup

    Workup for abnormal NIPT with suspected maternal malignancy

    Initial maternal and fetal workup: Complete targeted fetal evaluation (detailed fetal anatomy scan, amniocentesis/CVS if applicable) and targeted maternal clinical/lab workup (history, physical, CBC, peripheral smear, LDH, liver and renal function, tumor markers) and targeted imaging as indicated

    If maternal workup identifies a suspected source, pursue targeted imaging; if no source identified proceed to whole body MRI

    Whole body MRI indication: If targeted clinical and imaging workup does not reveal a potential maternal source for abnormal NIPT, Whole Body MRI (CPT 76498) is medically necessary

    Gadolinium should be avoided during pregnancy when possible

    Imaging for abnormal NIPT suspicious for maternal malignancy

    Covered when the following sequence is completed and criteria met:

    Prerequisite fetal evaluation: Complete fetal evaluations to rule out fetal source, including detailed fetal anatomy scan and invasive fetal diagnostic testing if applicable
    Maternal targeted clinical and laboratory evaluation: Complete history, physical, and appropriate laboratory workup (CBC, peripheral smear, LDH, liver and renal function testing, appropriate tumor markers) to evaluate for possible maternal malignancy
    Targeted imaging if indicated: If clinical workup reveals a suspected source, perform targeted imaging depending on suspected source (e.g., mammogram, chest x-ray, liver ultrasound)
    Persistent unexplained abnormal NIPT: If targeted clinical and imaging workup does not reveal a potential maternal source, Whole Body MRI (CPT 76498) is medically necessary

    Molar pregnancy and GTN imaging

    Covered when standard management steps are followed:

    Initial imaging: Ultrasound is the initial medically necessary study for suspected molar pregnancy
    Peri-evacuation imaging: Individuals should undergo chest x-ray pre- and post-evacuation; if chest x-ray positive for metastases manage per GTN/Oncology guidelines
    Post-evacuation surveillance: Serum hCG levels are obtained every 1–2 weeks after treatment until they normalize; rising or plateauing hCG post-evacuation warrants GTN management pathwayhCG every 1-2 weeks until normalization

    Molar pregnancy

    Molar pregnancy imaging and follow-up

    Initial diagnosis and management: Obstetrical ultrasound is the initial medically necessary study; once diagnosed treatment is usually evacuation; obtain chest x-ray pre- and post-evacuation

    If chest x-ray positive for metastases follow GTN guidelines

    Post-evacuation surveillance: Serum hCG levels are obtained every 1–2 weeks after treatment until normalization; rising or plateauing hCG post-evacuation warrants evaluation for GTNhCG every 1-2 weeks until normalization

    Erectile dysfunction / Priapism

    Erectile dysfunction and priapism

    ED initial and advanced imaging: Penile Doppler ultrasound (CPT 93980) is medically necessary if erectile dysfunction suspected; CTA pelvis with contrast (CPT 72191) is medically necessary if large-vessel vascular insufficiency is suspected following ultrasound

    Functional MRI or PET are not medically necessary for this indication

    Priapism evaluation: For non-ischemic priapism, penile Doppler ultrasound (CPT 93980) is medically necessary; if embolization is planned, CTA (CPT 72191) or MRA pelvis (CPT 72198) is medically necessary for pre-procedural planning; if priapism >24–48 hours or refractory, MRI pelvis (CPT 72197 or CPT 72195) is medically necessary24-48 hours

    Penile mass / Peyronie's disease

    Penile soft tissue mass and Peyronie's disease

    Initial evaluation: Penile ultrasound (CPT 76857) is medically necessary for initial evaluation of soft-tissue lesions of the penis; duplex Doppler (CPT 93975/93976) is medically necessary as an add-on; biopsy if primary penile cancer suspected
    Advanced imaging: MRI pelvis without and with contrast (CPT 72197) is medically necessary if ultrasound is equivocal and surgery or injection therapy is being contemplated for Peyronie's disease or penile lesions

    Chronic pelvic pain / Prostate disorders

    Male pelvic pain and prostate disorders

    Initial male pelvic pain imaging: Transabdominal pelvic ultrasound (bladder and prostate CPT 76856 or CPT 76857) is medically necessary as initial imaging for evaluation of pelvic pain related to male pelvic organs
    When ultrasound equivocal: CT pelvis with contrast (CPT 72193) OR MRI pelvis without contrast (CPT 72195) OR MRI pelvis with and without contrast (CPT 72197) is medically necessary if ultrasound is equivocal or nondiagnostic and alternative clinical conditions are being considered
    Prostate imaging for BPH or abscess: Suspected BPH with obstructive voiding: transrectal ultrasound (CPT 76872) or transabdominal ultrasound (CPT 76856/76857) is medically necessary; for prostatitis with urinary retention or suspected abscess, transrectal or transabdominal ultrasound, or CT pelvis with contrast or MRI pelvis (72195/72197) if ultrasound equivocal
    PAE planning: MRA pelvis (CPT 72198) or CTA pelvis (CPT 72191) is medically necessary for evaluation of pelvic vasculature if prostate artery embolization is planned; CPT 37243 includes intraprocedural imaging and additional advanced imaging during the procedure is not medically necessary

    Evaluation of Pelvic Pain / CPPS

    Pelvic pain / Chronic Pelvic Pain Syndrome

    Initial evaluation: Comprehensive history, physical exam, laboratory studies, and consideration of cystoscopy, urodynamics, and/or imaging when diagnosis is unclear
    Initial imaging: Transabdominal pelvic ultrasound (bladder and prostate CPT 76856 or CPT 76857) is medically necessary as initial imaging

    Proceed to cross-sectional imaging if ultrasound equivocal or nondiagnostic

    Advanced imaging: CT pelvis with contrast (CPT 72193) OR MRI pelvis without contrast (CPT 72195) OR MRI pelvis with and without contrast (CPT 72197) is medically necessary if ultrasound is equivocal or nondiagnostic and alternative clinical conditions are being considered

    Prostate Imaging Criteria

    Prostate disorders

    BPH with obstructive voiding: Transrectal ultrasound (CPT 76872) or transabdominal pelvic ultrasound (CPT 76856 or 76857) is medically necessary
    Prostatitis with retention or suspected abscess: Transrectal ultrasound (CPT 76872) or transabdominal pelvic ultrasound (CPT 76856 or 76857) is medically necessary; CT pelvis with contrast (CPT 72193) or MRI pelvis (CPT 72195/72197) is medically necessary if ultrasound is equivocal for abscess or mass
    PAE preprocedural imaging: MRA pelvis (CPT 72198) or CTA pelvis (CPT 72191) is medically necessary for evaluation of pelvic vasculature if prostate artery embolization is planned; CPT 37243 is inclusive of intraprocedural imaging and additional advanced imaging during the procedure is not medically necessary

    Hematospermia Imaging Criteria

    Hematospermia

    Indications for MRI: MRI pelvis without contrast (CPT 72195) or with and without contrast (CPT 72197) is medically necessary to evaluate for any of: age ≥40; recurrent hematospermia regardless of age; hematospermia with associated signs/symptoms (pain, fever, leukocytosis, hematuria); or abnormal findings on transrectal ultrasound

    Proctalgia Imaging Criteria

    Proctalgia syndromes / rectal pain

    Prior evaluation: Prior to advanced imaging the evaluation should include BOTH digital rectal exam and recent flexible sigmoidoscopy or colonoscopy subsequent to symptom onset to exclude inflammatory conditions or malignancy

    Imaging (endoanal ultrasound CPT 76872, MRI CPT 72197, or CT CPT 72193) is medically necessary after these studies have been performed or if labs/clinical info suggest infection/abscess/inflammation

    Interstitial Cystitis/Bladder Pain Syndrome

    Bladder - IC/BPS

    Initial workup: Workup should include history, physical, laboratory exam (urinalysis and urine culture), cystoscopy, and measurement of post void residual urine
    Imaging: Pelvic ultrasound (CPT 76856 or 76857) is medically necessary; CT pelvis with contrast (CPT 72193) is medically necessary if ultrasound is equivocal for complicated interstitial cystitis/bladder pain syndrome

    Scrotal Pathology Imaging Criteria

    Scrotal pathology

    Initial scrotal evaluation: Scrotal ultrasound (CPT 76870) and/or Duplex (Doppler) ultrasound (CPT 93975 or CPT 93976) for initial evaluation is medically necessary
    If ultrasound inconclusive: MRI pelvis without and with contrast (CPT 72197) or Tc-99m scrotal scintigraphy (CPT 78761) is medically necessary if ultrasound is inconclusive
    Varicocele/right-sided suspicion: CT abdomen and pelvis with contrast (CPT 74177) is medically necessary for right-sided varicocele when there is suspicion for intra-abdominal pathology

    Covered Indications (Modality-Specific)

    Ultrasound indications and modality selection

    Ultrasound indications and modality selection

    Transvaginal ultrasound (CPT 76830) is the optimal study to evaluate adult female pelvic organ pathology and is the preferred first-line modality

    Pelvic ultrasound (CPT 76856/76857) may complement or substitute in pediatric/non-sexually active individuals

    Transperineal uses: Transperineal ultrasound (CPT 76872) is medically necessary for suspected urethral abnormalities, urinary incontinence, pelvic prolapse, or vaginal cysts
    3D rendering use cases: 3D/4D rendering CPTs (76376/76377) are appropriate when ultrasound suggests uterine anomaly, intra-cavitary lesion, hydrosalpinx/peritoneal cyst, indeterminate infertility ultrasound, or lost IUD

    3D/4D ultrasound rendering for gynecologic and certain obstetrical indications

    3D/4D ultrasound rendering for gynecologic and certain obstetrical indications

    3D/4D uses: Suspected uterine anomaly, indeterminate intracavitary lesion, hydrosalpinx/peritoneal cysts when initial US equivocal, indeterminate infertility ultrasound, lost IUD, abnormal implantation sites, and fetal surgical planning cases

    CPT 76376/76377 appropriate

    Doppler ultrasound adjunctive use

    Doppler ultrasound adjunctive use

    Doppler adjunct: Duplex/Color Doppler (CPT 93975/93976) is of benefit as an adjunct to ultrasound for evaluation of vascularity in adnexal masses, submucosal fibroids, endometrial polyps, ovarian torsion suspicion, or chronic pelvic pain

    Should not report CPTs 93975 and 93976 together in same session

    MRI pelvis as second-line or problem-solving modality

    MRI pelvis as second-line or problem-solving modality

    MRI indications: MRI pelvis (CPT 72195/72197) is indicated when ultrasound is inconclusive (e.g., adenomyosis, indeterminate adnexal masses, deep pelvic endometriosis) or when iodinated contrast allergy exists, and for surgical planning when ultrasound is inadequate

    MRI can change management in indeterminate adnexal masses

    CPT and Procedural Codes

    Referenced CPT codes (ultrasound and associated procedures)CPT
    76830Transvaginal ultrasound
    76856Pelvic ultrasound, complete
    76857Pelvic ultrasound, limited
    76872Transperineal ultrasound
    76942Ultrasound guidance for needle placement
    763763D rendering (no independent workstation)
    763773D rendering (requires independent workstation)
    93975Duplex scan (complete) arterial inflow and venous outflow of abdominal/pelvic/scrotal contents
    93976Duplex scan (limited) arterial inflow and venous outflow of abdominal/pelvic/scrotal contents
    76870Ultrasound scrotum and contents
    3D/4D Ultrasound Rendering CPTsCPTCovered
    763763D rendering not requiring image post-processing on an independent workstation
    763773D rendering requiring image post-processing on an independent workstation
    Other Ultrasound CPTsCPT
    93975Duplex scan (complete) of arterial inflow and venous outflow of abdominal, pelvic, scrotal contents and/or retroperitoneal organs
    93976Duplex scan (limited) of arterial inflow and venous outflow of abdominal, pelvic, scrotal contents and/or retroperitoneal organs
    Pelvic MRI CPTsCPTCovered
    72195MRI pelvis without contrast
    72196MRI pelvis with contrast only
    72197MRI pelvis without and with contrast
    Referenced Procedural CPT CodesCPT
    76856Pelvic ultrasound; complete
    76857Pelvic ultrasound; limited or follow-up
    76830Transvaginal ultrasound
    93975Duplex scan of pelvic vessels, complete
    93976Duplex scan of pelvic vessels, limited
    763773-D rendering (add-on)
    72194CT pelvis with and without contrast
    72195MRI pelvis without contrast
    72197MRI pelvis without and with contrast
    74740Hysterosalpingogram
    1–10 of 11
    1/2
    Referenced imaging CPT codesCPT
    76856Pelvic ultrasound (complete)
    76857Pelvic ultrasound (limited)
    76830Transvaginal ultrasound
    72195MRI pelvis without contrast
    72197MRI pelvis without and with contrast
    72198MRA pelvis
    72191CTA pelvis
    763763D rendering
    763773D rendering, advanced
    93975Duplex (Doppler) scan, complete
    1–10 of 11
    1/2
    Referenced imaging CPT codes (additional)CPT
    76830Transvaginal ultrasound
    76856Pelvic ultrasound, complete
    76857Pelvic ultrasound, limited or follow-up
    763763D rendering with interpretation
    763773D rendering post-processing
    72197MRI Pelvis without and with contrast
    72195MRI Pelvis without contrast
    93975Duplex (Doppler) scan, complete
    93976Duplex (Doppler) scan, limited
    Covered ultrasound CPT codes for suspected endometriosisCPTCovered
    76830Transvaginal ultrasound
    76856Transabdominal pelvic ultrasound; complete
    76857Transabdominal pelvic ultrasound; limited
    Covered MRI CPT codes for specified indicationsCPTCovered
    72195MRI pelvis without contrast
    72197MRI pelvis without and with contrast
    Covered CPT Codes (infertility/IUD/etc.)CPTCovered
    76856Pelvic ultrasound; complete
    76857Pelvic ultrasound; limited
    76830Transvaginal ultrasound
    74740Hysterosalpingography
    76831Sonohysterosalpingography
    763773D US imaging (add-on)
    93975Ultrasound color Doppler (complete)
    93976Ultrasound color Doppler (limited)
    72192CT Pelvis without contrast
    74176CT Abdomen and Pelvis without contrast
    1–10 of 17
    1/2
    Covered CPT Codes (multi-section)CPT
    76830Transvaginal ultrasound
    76856Pelvic ultrasound, complete
    76857Pelvic ultrasound, limited or follow-up
    93975Duplex scan (complete)
    93976Duplex scan (limited)
    72193CT pelvis with contrast
    72195MRI pelvis without contrast
    72197MRI pelvis without and with contrast
    76700Abdominal ultrasound, complete
    76705Abdominal ultrasound, limited or follow-up
    1–10 of 11
    1/2
    Initial Pelvic Ultrasound CodesCPTCovered
    76856Transabdominal pelvic ultrasound (bladder and prostate) - complete
    76857Transabdominal pelvic ultrasound - limited or alternate listing (bladder/prostate)
    Transrectal / Endoanal UltrasoundCPTCovered
    76872Transrectal / Endoanal ultrasound
    Benign-size threshold for simple ovarian cysts
    Benign-size threshold for simple ovarian cystsSimple ovarian cysts up to 10 cm by ultrasound are almost universally benign
    Follow-up for cysts ≤3 cmPre- and post-menopausal: no routine follow-up required
    Follow-up for cysts >3 to 5 cmPre-menopausal: no follow-up; Post-menopausal: follow-up at 12 months with TV and/or pelvic ultrasound; if smaller stop surveillance; if stable repeat at 24 months; if enlarging follow at 12 and 24 months
    Follow-up for cysts >5 to ≤10 cmPre-menopausal: follow-up in 8–12 weeks (proliferative phase if possible) with TV and/or pelvic ultrasound; Post-menopausal: follow-up in 3–6 months; subsequent annual follow-up until stable for 2 years or decreasing, then stop
    Cyst size thresholds
    Cyst size categoriesDefined size thresholds: ≤3 cm; >3 to 5 cm; >5 to ≤10 cm; >10 cm
    Management for >10 cm cystsIf not excised, ultrasound follow-up within 6 months; if stable, follow at 12 and 24 months; MRI pelvis (CPT 72197) is medically necessary if solid component, equivocal ultrasound, or changing morphology/vascularity
    Escalation when morphology changesAny change in morphology on follow-up imaging prompts evaluation under Complex Adnexal Masses and may require MRI (CPT 72197)
    Endometrial thickness threshold
    Endometrial thickness threshold (postmenopausal)Endometrial thickness >4 mm may prompt individualized assessment and consideration of endometrial sampling
    Evaluation approachAn incidentally discovered thickened endometrium (>4 mm) in an asymptomatic postmenopausal individual does not routinely require evaluation but warrants individualized assessment based on risk factors
    Imaging for EIN-AEHAdvanced imaging is not medically necessary for Endometrial Intraepithelial Neoplasia or Atypical Endometrial Hyperplasia as it has not been shown to improve outcomes

    Provider Responsibilities, Prior Authorization, and Documentation

    Prior Authorization

    eviCore review requirement

    These coverage policies are used by medical directors and other professionals in making medical necessity and other coverage determinations for Cigna-administered plans; certain high‑tech imaging procedures are reviewed by eviCore per the Cigna CPT code list. In the event of conflict, the applicable benefit plan document supersedes the policy.

    Prior Authorization

    Prior authorization applies to listed pelvic imaging CPTs

    Prior authorization and review processes apply to the listed pelvic imaging CPTs identified in the guideline (for example, 3D/4D ultrasound rendering CPTs 76376/76377 and pelvic MRI CPTs 72195/72196/72197) when requested in the specified scenarios.

    Prior Authorization

    Advanced cross-sectional imaging requires prior justification

    CT pelvis (e.g., CPT 72194) or MRI pelvis (CPT 72195/72197) should only be obtained when ultrasound (with color Doppler) is equivocal and further cross‑sectional imaging is needed for surgical planning or to resolve indeterminate results.

    Prior Authorization

    Prior authorization for MRI/MRA/CTA when ultrasound inconclusive or for procedural planning

    MRI (CPT 72195/72197) and vascular cross‑sectional imaging (MRA CPT 72198 or CTA CPT 72191) are medically necessary as second‑line studies when ultrasound is inconclusive or when required for interventional/embolization planning.

    Prior Authorization

    Imaging follow-up and MRI authorization

    Follow‑up pelvic/transvaginal ultrasound (CPT 76830, 76856, 76857) is supported per the guideline schedules; MRI Pelvis without and with contrast (CPT 72197) is medically necessary when indicated (e.g., equivocal ultrasound, solid component, changing morphology).

    Prior Authorization

    Prior authorization expectations

    MRI Pelvis (CPT 72195 or 72197) is medically necessary only for specified indications (e.g., preoperative planning for deep pelvic endometriosis, characterization of complex adnexal masses when ultrasound is equivocal); documentation must support the specific indication.

    Prior Authorization

    Imaging prior authorization considerations

    Pelvic ultrasound (CPT 76856/76857 or 76830) and/or color Doppler (CPT 93975/93976) are medically necessary as initial imaging when diagnosis remains uncertain after exam and labs; CT or MRI require justification when ultrasound is inconclusive or for abscess/TOA planning.

    Prior Authorization

    Imaging prior authorization guidance

    A one‑time pelvic ultrasound (CPT 76856/76857) and/or transvaginal ultrasound (CPT 76830) is medically necessary for initial infertility evaluation; CT or MRI for lost IUD localization is medically necessary only when ultrasound and plain x‑ray are negative or non‑diagnostic.

    Prior Authorization

    Prior authorization for advanced pelvic imaging

    Obtain prior authorization per payer rules when ordering CT pelvis with contrast (CPT 72193) or MRI pelvis (CPT 72195/72197) for chronic pelvic pain, surgical planning, or other advanced pelvic imaging after equivocal ultrasound.

    Prior Authorization

    Advanced vascular imaging for planning

    For embolization or other vascular procedural planning, MRI pelvis (CPT 72195/72197) may be used; if MR is equivocal or the interventionalist requests vascular mapping, MRA (CPT 72198) or CTA (CPT 72191) may be obtained with prior authorization as indicated.

    Prior Authorization

    Prior authorization for specified advanced imaging

    Advanced imaging such as MRI Pelvis (CPT 72197) and certain CT/MRI abdomen or pelvis studies are medically necessary in defined situations (e.g., surgical planning, indeterminate ultrasound) and are subject to payer prior authorization processes.

    Prior Authorization

    Prior authorization for select MRI studies

    Per eviCore rules, fetal MRI (CPT 74712) and Whole Body MRI (CPT 76498) require prior authorization per the guideline when requested in the described clinical sequences.

    Prior Authorization

    Whole Body MRI for unexplained abnormal NIPT

    Whole Body MRI (CPT 76498) is authorized when targeted fetal and maternal workup are completed and unrevealing for abnormal NIPT suggesting possible maternal malignancy.

    Billing Rule

    Embolization imaging inclusivity

    CPT 37243 (vascular embolization) includes radiological supervision/interpretation, intraprocedural roadmapping, and imaging guidance required to complete the intervention; additional advanced imaging codes during the procedure are not medically necessary.

    Prior Authorization

    Preprocedural Vascular Imaging for PAE

    When prostate artery embolization (PAE) is planned, MRA pelvis (CPT 72198) or CTA pelvis (CPT 72191) is medically necessary for preprocedural evaluation of pelvic vasculature; document that vascular mapping was ordered for PAE planning.

    • MRA (CPT 72198) or CTA (CPT 72191) required for PAE planning
    • Document vascular evaluation ordered as part of PAE planning
    Step Therapy

    Imaging step requirement

    Non‑advanced imaging (e.g., pelvic/transvaginal ultrasound) and appropriate laboratory testing are expected prior to ordering advanced imaging when clinically appropriate; perform and document initial workup before escalation.

    Step Therapy

    Imaging modality sequencing

    Ultrasound is recommended as the first‑line imaging modality for female pelvic disorders; reserve MRI as a second‑line or problem‑solving modality when ultrasound is inconclusive or specific indications are met.

    Step Therapy

    Begin with pregnancy testing and ultrasound before advanced imaging

    Begin with pregnancy testing and pelvic/transvaginal ultrasound before advanced imaging; add color Doppler and 3‑D rendering as adjuncts when ultrasound is equivocal and prior to CT/MRI if clinically appropriate.

    Step Therapy

    Initial imaging should be ultrasound before MRI except specific circumstances

    Initial imaging for most pelvic indications should be ultrasound (transvaginal or transabdominal); MRI is reserved for defined situations (e.g., pregnancy where MRI without contrast preferred, indeterminate ultrasound, surgical planning).

    Step Therapy

    Ultrasound before MRI for adnexal masses

    When ultrasound incompletely evaluates a complex or solid adnexal mass, repeat ultrasound is generally medically necessary; a single MRI Pelvis without and with contrast (CPT 72197) is medically necessary in specified situations (e.g., poor visualization, unexplained change, O‑RADS 3 with solid component, O‑RADS 4–5).

    Step Therapy

    Imaging step therapy

    Stepwise imaging approach: perform transabdominal and/or transvaginal ultrasound first; reserve MRI for the listed indications when ultrasound is indeterminate or for surgical planning.

    Step Therapy

    Ultrasound first for PID and PCOS; labs before advanced imaging

    Recommend initial use of pelvic transabdominal and/or transvaginal ultrasound before CT or MRI for evaluation of PID and PCOS; obtain recommended laboratory testing (e.g., virilizing hormones for PCOS) prior to advanced imaging.

    Step Therapy

    IUD localization workflow: ultrasound → X‑ray → CT/MRI

    For suspected malpositioned or 'lost' IUD perform ultrasound first; if ultrasound is non‑diagnostic and pregnancy test is negative, obtain plain X‑ray; if both ultrasound and X‑ray are equivocal, escalate to CT or MRI to delineate position.

    • Ultrasound initial
    • If US non‑diagnostic and pregnancy negative → X‑ray
    • If US + X‑ray equivocal → CT or MRI
    Step Therapy

    Ultrasound required as initial step; document pregnancy test

    Ultrasound (transabdominal and/or transvaginal) is required as the initial imaging step before advanced modalities for suspected gynecologic pelvic pain or malpositioned IUD; document pregnancy test for premenopausal patients.

    Step Therapy

    Transvaginal ultrasound as initial study for uterine mass

    Transvaginal ultrasound (CPT 76830) is the medically necessary initial study for suspected uterine mass; pelvic ultrasound (CPT 76856/76857) may be complementary before advancing to MRI for indeterminate findings or surgical planning.

    Note

    Ultrasound often first-line but not always mandatory

    Ultrasound is appropriate initial imaging for many indications but is not always required prior to advanced imaging (e.g., urethral diverticula may proceed to urethrography/CT or MRI without a mandatory prior ultrasound when clinically appropriate).

    Step Therapy

    Stepwise imaging approach

    Stepwise imaging: begin with ultrasound (including 3‑D when appropriate); proceed to MRI or CT only when ultrasound is indeterminate or additional detail for surgical planning is required.

    Step Therapy

    Required stepwise workup before Whole Body MRI for abnormal NIPT

    Complete prerequisite fetal evaluation (detailed fetal anatomy scan and invasive fetal testing if applicable) and targeted maternal clinical/laboratory workup and imaging before authorizing Whole Body MRI when abnormal NIPT suggests maternal‑origin anomalies.

    • Detailed fetal anatomy scan and fetal testing (amniocentesis/CVS) if indicated
    • Complete maternal history, physical, labs and targeted imaging
    • Proceed to Whole Body MRI (CPT 76498) only if targeted workup unrevealing
    Step Therapy

    Stepwise imaging approach for male pelvic/penile indications

    For penile lesions, ED, and male pelvic pain start with ultrasound; advance to CT/CTA/MRI/MRA only if ultrasound is equivocal, nondiagnostic, or vascular/oncologic evaluation or procedural planning is required.

    Step Therapy

    Imaging Stepwise Requirement for male pelvic pain/prostate

    Perform transabdominal pelvic ultrasound (CPT 76856/76857) as initial imaging for male pelvic pain/prostate evaluation; proceed to CT pelvis with contrast (CPT 72193) or MRI pelvis (CPT 72195/72197) only if ultrasound is equivocal or nondiagnostic.

    Documentation Required

    Required clinical evaluation before advanced imaging

    A current clinical evaluation since onset or change in symptoms is required before advanced imaging; acceptable elements include history, pelvic/urologic exam, appropriate labs, and non‑advanced imaging such as plain x‑ray or ultrasound.

    Documentation Required

    Acceptable substitute for in‑person evaluation

    Other meaningful contact (telehealth, telephone, electronic messaging) since onset or change in symptoms by an established individual may substitute for a face‑to‑face clinical evaluation.

    Billing Rule

    Coding guidance for 3D rendering and pelvic MRI

    When billing for 3‑D rendering report CPT 76376 or 76377 as appropriate; report MRI pelvis with CPT 72195, 72196, or 72197 depending on contrast protocol per the guideline and payer coding rules.

    Documentation Required

    Pregnancy test and documentation requirements

    Pregnancy test result must be documented for premenopausal patients when imaging for pelvic indications (e.g., pelvic pain, IUD localization); if pregnancy test is positive, obstetrical CPT coding is required instead of gynecology CPTs.

    • Document pregnancy test result prior to imaging in premenopausal patients
    • If positive, use obstetrical CPT codes and follow obstetrical imaging policy
    Documentation Required

    Document indication, relevant exam findings, prior imaging

    Ordering documentation should include the clinical indication, relevant exam findings (e.g., suspected mass, simple versus complex cyst features), prior ultrasound results if repeating, pregnancy status, and whether transvaginal approach is acceptable/consented.

    Documentation Required

    Pre‑menopausal and post‑menopausal evaluation labs and tests

    For pre‑menopausal evaluation consider pregnancy test (quantitative hCG if ectopic suspected), CBC/hematocrit, and cultures as clinically indicated; for post‑menopausal evaluation obtain tumor markers (e.g., CA‑125) when evaluating complex cysts or solid masses.

    Documentation Required

    Required clinical documentation to support MRI requests

    Ordering documentation must support first‑line use of transvaginal and/or transabdominal pelvic ultrasound and explicitly state the reason for MRI when requested (e.g., planned surgery for deep infiltrative endometriosis, indeterminate adnexal mass after US, suspected extrapelvic endometriosis, or inconclusive ultrasound for abdominal wall/cesarean scar disease).

    Documentation Required

    Documentation should include clinical exam findings and lab results

    Documentation should include clinical examination findings, results of laboratory testing (e.g., WBC, CRP, ESR, microscopy of vaginal secretions, testing for N. gonorrhoeae and C. trachomatis), and rationale for advanced imaging if ultrasound is inconclusive or TOA suspected.

    Documentation Required

    Pregnancy test documentation for lost IUD imaging

    Pregnancy test result must be documented when imaging for a lost IUD; a positive pregnancy requires obstetrical coding and different supported imaging workflows.

    Documentation Required

    Document pregnancy test result and initial ultrasound findings

    Document pregnancy test result for premenopausal patients and initial ultrasound findings; if ultrasound is equivocal, document the rationale for proceeding to X‑ray (for IUD) or CT/MRI for pelvic pain evaluation.

    Documentation Required

    Negative pregnancy test and sampling guidance for leiomyoma/endometrium

    A negative pregnancy test is required for premenopausal patients when ultrasound is performed for suspected leiomyoma with symptoms or enlarged uterus on exam; individualized assessment including endometrial sampling is medically necessary for postmenopausal thickened endometrium (>4 mm).

    Documentation Required

    Document clinical indication and prior imaging to support advanced imaging

    Clinical indication and prior imaging results should be documented to support the use of advanced imaging modalities (e.g., ultrasound indeterminate or imaging requested for surgical planning).

    Documentation Required

    Documentation for abnormal NIPT workup

    Complete clinical workup documentation (history, physical, labs, tumor markers, targeted imaging) is required to support proceeding to Whole Body MRI when abnormal NIPT persists without an identified maternal source.

    • History and physical
    • CBC, peripheral smear, LDH, liver and renal function
    • Appropriate tumor markers and targeted imaging results
    Documentation Required

    Workup documentation before Whole Body MRI

    Document complete history, physical exam, and results of appropriate laboratory testing (CBC, peripheral smear, LDH, liver and renal function, tumor markers) and targeted imaging results before whole body MRI is authorized when abnormal NIPT suggests possible maternal malignancy.

    Documentation Required

    Documentation should include clinical indication and initial ultrasound results

    Clinical documentation should include the indication (e.g., suspected ED, priapism duration, biopsy‑proven penile cancer, suspected prostate abscess or BPH with obstructive symptoms, molar pregnancy and hCG trend) and results of initial ultrasound when performed to support advanced imaging or procedural vascular mapping.

    Documentation Required

    Required clinical documentation (proctalgia and pelvic pain)

    Clinical documentation should include history, physical exam findings, and results of initial ultrasound (when performed). For proctalgia, document digital rectal exam and recent sigmoidoscopy/colonoscopy or clinical/lab evidence prompting imaging.

    Documentation Required

    PAE Imaging Documentation

    For PAE planning, documentation should indicate that MRA or CTA pelvis was ordered for vascular evaluation as part of preprocedural planning; note that CPT 37243 includes intraprocedural imaging.

    Note

    Coverage determinations and plan document precedence

    Coverage determinations require consideration of the applicable benefit plan document, laws/regulations, and relevant collateral materials; failure to follow plan terms or applicable rules may trigger denial.

    Denial Risk

    CT not medically necessary for pelvic anatomy

    CT is not medically necessary for evaluating pelvic anatomy due to limited soft tissue contrast resolution; use of CT as a primary modality for pelvic soft‑tissue evaluation may trigger denial.

    Denial Risk

    MRI not appropriate as initial imaging for AUB

    Requests for MRI as initial imaging for abnormal uterine bleeding or routine CT for AUB may be denied when ultrasound is the indicated first‑line modality; MRI is not indicated as initial imaging for AUB per the guideline.

    Denial Risk

    Routine 3D rendering for simple cysts not medically necessary

    Routine use of 3‑D rendering (CPT 76376/76377) for evaluation of simple ovarian cysts is not medically necessary and may be denied; reserve 3‑D rendering for the specified indications where it is described as medically necessary.

    Denial Risk

    Indication-based MRI authorization risk

    Use of MRI must align with specified indications (e.g., preoperative planning for deep pelvic endometriosis, characterization of complex adnexal masses after inconclusive ultrasound); requests outside those indications risk denial.

    Denial Risk

    Failure to show uncertainty after exam/labs may risk denial

    Failure to document that the diagnosis remained uncertain after clinical exam and laboratory testing when ordering pelvic ultrasound, CT, or MRI for suspected PID or TOA may lead to denial of imaging requests.

    Denial Risk

    Repeat/serial ultrasounds for infertility not medically necessary

    Repeat or serial ultrasounds for initial infertility workup are designated not medically necessary and may be denied; only a one‑time pelvic/transvaginal ultrasound is medically necessary for initial infertility evaluation.

    Billing Rule

    Gynecology CPTs not supported in pregnancy

    Use of gynecology CPT codes for pregnant women is not supported; obstetrical CPT codes must be used if pregnancy test is positive — using non‑obstetrical CPTs in pregnancy may trigger denial.

    Denial Risk

    Failure to document pregnancy test may lead to inappropriate imaging

    Failure to document a pregnancy test in premenopausal females prior to imaging for pelvic pain may lead to inappropriate imaging selection and potential denial; always document pregnancy status.

    Denial Risk

    CT not appropriate for pelvic soft‑tissue anatomy

    CT is not medically necessary for evaluating female pelvic anatomy because of limited soft tissue contrast resolution; ordering CT as the primary modality for pelvic soft‑tissue evaluation risks denial.

    Denial Risk

    Advanced imaging not medically necessary for known arcuate uterus

    Advanced imaging for a known arcuate uterus is not medically necessary and claims for advanced imaging solely for a confirmed arcuate uterus may be denied.

    Denial Risk

    Denial risk for incomplete abnormal NIPT workup

    Failure to complete the recommended maternal workup (history, physical, labs, targeted imaging) or failure to perform whole body MRI when targeted workup is unrevealing in abnormal NIPT cases may lead to denial of whole body MRI or alternative imaging requests.

    Denial Risk

    Risk when advanced imaging ordered without equivocal ultrasound

    Ordering advanced imaging (CT or MRI) when initial ultrasound is not equivocal or nondiagnostic may not meet the guideline's stepwise requirement and could risk denial; document why ultrasound was insufficient.

    Denial Risk

    Initial Ultrasound Requirement — perform and document

    Failure to perform or document an initial transabdominal pelvic ultrasound when indicated may lead to denial if advanced imaging is requested without ultrasound being equivocal or nondiagnostic.

    Prior Authorization and High-Tech Imaging

    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note

    Contrast and Pregnancy Considerations

    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note

    Imaging Frequency and Follow-up Intervals

    inv-239: Ultrasound one-time; repeat if symptoms persist
    Initial ultrasound frequencyOne-time pelvic ultrasound (transabdominal and/or transvaginal) is medically necessary for initial evaluation; repeat ultrasound is medically necessary only if symptoms persist.
    Use of color DopplerColor Doppler (CPT 93975/93976) may be added to assist diagnosis when evaluating for retained products or vascularity concerns.
    When to escalateIf ultrasound with color Doppler is equivocal and further imaging needed for surgical planning, CT pelvis (72194) or MRI pelvis (72197) is medically necessary.
    inv-240: Ultrasound follow-up intervals by size and menopausal status
    Follow-up intervals by size & menopausal statusFollow-up intervals vary by cyst size and menopausal status (examples: 8–12 weeks for >5–≤10 cm pre‑menopausal; 3–6 months for >5–≤10 cm post‑menopausal; 12 and 24 months surveillance for selected lesions).
    ≤3 cmPre- and post-menopausal: no routine follow-up required.
    >3–5 cmPost-menopausal: follow-up at 12 months (then 24 months if stable); pre‑menopausal often requires no follow-up.
    >5–≤10 cmPre-menopausal: follow-up in 8–12 weeks (proliferative phase if possible); Post‑menopausal: follow-up in 3–6 months; annual surveillance until stable for 2 years.
    inv-241: Ultrasound one-time for infertility initial evaluation
    Initial infertility ultrasoundA one-time pelvic ultrasound (CPT 76856/76857) and/or transvaginal ultrasound (CPT 76830) is medically necessary for initial infertility evaluation.
    Repeat ultrasoundsRepeat or serial ultrasounds for initial infertility workup are not medically necessary.
    Adjuncts if indeterminateIf ultrasound is indeterminate, 3D US imaging (add-on CPT 76377) or color Doppler (CPT 93975/93976) are medically necessary.

    Not Medically Necessary / Not Covered

    CT is generally not medically necessary for primary evaluation of female pelvic anatomy because it provides inferior soft-tissue contrast compared with ultrasound and MRI. The guideline states that CT is limited for pelvic soft-tissue delineation and is not the recommended first-line modality for assessing uterine, adnexal, or endometrial pathology. CT may be considered only in select situations (for example when CT is the only readily available modality for an urgent diagnosis), but routine use for pelvic anatomy is discouraged and may not meet medical necessity criteria.

    CT is described in the policy as not medically necessary for evaluation of pelvic soft-tissue anatomy because it is limited by suboptimal soft-tissue contrast resolution. For evaluation of adnexal or ovarian lesions, the guideline endorses ultrasound as the primary modality and reserves cross-sectional imaging (MRI) for problem-solving when ultrasound is indeterminate.

    For abnormal uterine bleeding (AUB) the guideline requires pregnancy testing when appropriate and specifies pelvic/transvaginal ultrasound as the first-line imaging study. MRI is not supported as an initial imaging modality for AUB and is reserved as a problem-solving or second-line test when ultrasound cannot characterize the abnormality. Routine CT for AUB is similarly of limited utility and is not recommended.

    Routine use of 3‑D ultrasound rendering (CPT 76376 / 76377) for simple ovarian cysts is explicitly not medically necessary. Simple cysts (up to ≤ 10 cm) are almost universally benign and follow-up is based on size and menopausal status without routine 3‑D post‑processing; 3‑D rendering is reserved for specific indications when ultrasound is equivocal or intracavitary/structural detail is required.

    CT for evaluation of the female pelvis and routine additional advanced imaging during uterine artery embolization are described as not medically necessary. MRI and angiographic studies may be used for preprocedural vascular mapping if specifically requested for embolization planning, but interval CT after embolization and use of additional advanced imaging codes during the procedure are not supported because the vascular embolization code (CPT 37243) is inclusive of required intraprocedural imaging.

    Advanced imaging for a known arcuate uterus is considered unnecessary because an arcuate uterus is regarded as a normal variant; additional cross‑sectional imaging solely to evaluate a previously diagnosed arcuate uterus is not medically necessary. Likewise, routine pelvimetry (x‑ray, CT, or MRI) for delivery planning lacks sufficient evidence to be clinically useful and is not supported for routine practice.

    Definitions and Key Terms

    inv-174: Imaging anatomic boundaries
    Pelvic imaging boundariesPelvic imaging begins at the iliac crest and extends to the pubis.
    Abdominal imaging boundariesAbdominal imaging begins at the diaphragm and extends to the umbilicus or iliac crest.
    Organ extension ruleIf uterus or adnexa extend above the iliac crest/umbilicus on exam or prior imaging, abdominal imaging may be added to complete evaluation.
    inv-175: Pelvic organ definition/extension
    Pelvic organs definedThe uterus, fallopian tubes, and ovaries are considered pelvic organs.
    When to include abdomenIf pelvic organs are palpated or imaged above the iliac crest or umbilicus, abdominal imaging may be added.
    Implication for modalityTransvaginal, transabdominal, or transperineal ultrasound may be used depending on patient factors and organ location.
    inv-176: 3D/4D rendering definition
    Definition3D/4D rendering (CPT 76376, 76377) are ultrasound post‑processing techniques producing volumetric images to better characterize uterine anomalies, intracavitary lesions, adnexal pathology, or fetal malformations for diagnosis or surgical planning.
    When medically necessary3D/4D rendering is medically necessary for specified scenarios such as equivocal intracavitary lesions, lost IUDs, suspected uterine anomalies, indeterminate infertility ultrasound, and certain obstetrical surgical planning.
    Coding notesReport CPT 76376 or 76377 appropriately when billing; routine use for simple ovarian cysts is not medically necessary.
    inv-177: Asherman's syndrome
    DefinitionAsherman’s syndrome is an acquired condition characterized by scar tissue within the uterus.
    Imaging roleIf hysterosalpingogram, sonohysterosalpingography, or hysteroscopy is indeterminate for Asherman's, MRI pelvis (72195/72197) may be medically necessary.
    Clinical contextEndometrial sampling remains the gold standard for many intrauterine pathologies; imaging complements invasive assessment when indeterminate.
    inv-178: Simple cyst definition and benign threshold
    Simple cyst definitionSimple cysts are smooth‑walled, anechoic, clear without debris on ultrasound.
    Benign thresholdSimple cysts up to 10 cm in diameter measured by ultrasound are almost universally benign.
    Management noteRoutine 3D rendering for simple ovarian cyst evaluation is not medically necessary; follow-up imaging per size/menopausal status schedule.
    inv-179: Complex cyst definition
    Complex cyst featuresComplex cysts have solid areas or excrescences, debris, irregular septations >3 mm, mural nodules with Doppler flow, and/or free fluid.
    Imaging implicationsComplex features warrant closer follow-up and often MRI (CPT 72197) if ultrasound is equivocal or morphology/vascularity changes.
    O-RADS linkageComplex cysts are addressed within O-RADS risk stratification and may correspond to higher O-RADS categories prompting advanced imaging.
    inv-182: O-RADS
    O-RADS purposeO-RADS (ACR Ovarian‑Adnexal Reporting and Data System) standardizes reporting and risk stratifies adnexal lesions to guide management.
    Risk examplesO-RADS US Category 2 has very low malignancy risk (<1%); Category 5 indicates high risk (≥50%).
    Adjunct imagingFor indeterminate or higher‑risk O‑RADS categories, adjunct MRI is supported to aid preoperative triage.
    inv-183: MRI Pelvis CPT definitions (72195/72197)
    72195 definitionMRI pelvis without contrast (CPT 72195) — used for characterization when contrast not used or in pregnancy.
    72197 definitionMRI pelvis without and with contrast (CPT 72197) — used for characterization of adnexal masses and preoperative evaluation when contrast is appropriate.
    Usage noteMRI pelvis (72195/72197) is a second‑line modality after inconclusive ultrasound or when required for surgical planning; MRA/CTA may be used for vascular mapping.
    inv-184: Polycystic ovaries ultrasound definition
    PCOS ultrasound definitionPolycystic ovary defined as an ovary containing ≥12 follicles (or ≥25 with new ultrasound technology) measuring 2–9 mm, or ovarian volume >10 mL; one ovary meeting criteria is sufficient.
    Role of ultrasoundTransabdominal and/or transvaginal ultrasound is the modality of choice to assess follicle count and ovarian morphology in suspected PCOS.
    Laboratory adjunctsLaboratory testing (e.g., hormones) may direct imaging and exclude alternate etiologies prior to advanced imaging.
    inv-186: Sonohysterosalpingography
    DefinitionSonohysterosalpingography (SHG, CPT 76831) is an ultrasound‑based assessment of the uterine cavity and tubal patency; it is more operator dependent than HSG but avoids ionizing radiation.
    When usedSHG is medically necessary when ultrasound is indeterminate for intracavitary lesions or to evaluate tubal patency as an alternative to HSG.
    ComparisonHysterosalpingography (CPT 74740) remains an established method for tubal patency; SHG is a noninvasive ultrasound alternative depending on clinical context.
    inv-194: Arcuate uterus (normal variant)
    Arcuate uterusAn arcuate uterus is considered a normal variant; advanced imaging of a known arcuate uterus is not medically necessary.
    Initial evaluationPelvic and/or transvaginal ultrasound is medically necessary for initial evaluation of suspected congenital uterine anomalies; 3D rendering may be added if anomaly suspected.
    When MRI indicatedMRI pelvis (72197) is medically necessary when ultrasound is indeterminate for a complex uterine anomaly or when requested for surgical planning.

    Background and Scope

    Pelvic imaging evaluates the pelvic organs (uterus, fallopian tubes, ovaries) and related structures within the bony pelvis. The guideline emphasizes an ultrasound‑first approach: transvaginal ultrasound (CPT 76830) is the optimal initial test for most female pelvic indications, with transabdominal or transperineal ultrasound used when transvaginal access is not appropriate. MRI is a targeted, second‑line modality when ultrasound is inconclusive or when superior soft‑tissue characterization or surgical planning is required. CT is limited for pelvic soft‑tissue evaluation and is generally not appropriate as the primary imaging modality for pelvic anatomy.